Investors & Media Press Releases

Axovant Sciences Ltd. Announces Completion of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares


HAMILTON, Bermuda, June 16, 2015 /PRNewswire/ -- Axovant Sciences Ltd. (NYSE: AXON; "Axovant"), a clinical-stage biopharmaceutical company, today announced the completion of its initial public offering of 24,150,000 common shares, including 3,150,000 common shares sold pursuant to the full exercise of the underwriters' previously granted option to purchase additional common shares.  All of the common shares were offered by Axovant at a public offering price of $15.00 per share. The common shares of Axovant began trading under the ticker symbol "AXON" on June 11, 2015. The gross proceeds to Axovant from this offering, prior to deducting underwriting discounts and commissions and estimated offering expenses payable by Axovant, were approximately $362 million. 

Jefferies LLC, Evercore Group L.L.C. and RBC Capital Markets LLC acted as joint book-running managers for the offering. JMP Securities LLC acted as lead manager, and Robert W. Baird & Co. Incorporated acted as co-manager for the offering.

The offering was made only by means of a prospectus. Copies of the final prospectus related to the offering may be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, telephone: (877) 547-6340, e-mail:; Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 36th Floor, New York, NY 10055, telephone: (212) 653-9054 or email:; or RBC Capital Markets, LLC, Attention: Prospectus Department, Brookfield Place, 200 Vesey Street 8th Floor, New York, NY 10281, telephone: (877) 822-4089, email:  

A registration statement relating to these securities has been filed with the Securities and Exchange Commission and was declared effective on June 10, 2015. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Axovant
Axovant is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of novel therapeutics for the treatment of neurodegenerative disorders. Axovant intends to develop a pipeline of product candidates to comprehensively address the cognitive, behavioral and functional components of dementia, a condition characterized by significant decline in mental capacity and impaired daily function.

Logo -

SOURCE Axovant Sciences Ltd.

Jonathan Neely
Head, Investor Relations and Corporate Communications
Axovant Sciences, Inc.
(212) 634-9744